

1 **Relative vaccine effectiveness of a CoronaVac booster dose in preventing symptomatic SARS-CoV-2**
2 **infection among healthcare workers during an Omicron period in Azerbaijan, January–August 2022**

3 Iris Finci^{1*}, Madelyn Yiseth Rojas Castro^{2*}, Nabil Seyidov^{3*}, Samir Mehdiyev³, C. Jason McKnight¹,
4 Barbara Mühlemann^{4,5}, Christian Drosten^{4,5}, Lindsey Duca⁶, Richard Pebody¹, Esther Kissling², Mark A.
5 Katz¹, Gahraman Hagverdiyev³

6 1. World Health Organization Regional Office for Europe, Copenhagen, Denmark

7 2. Epiconcept, Paris, France

8 3. Public Health and Reforms Center, Ministry of Health, Azerbaijan Republic

9 4. Institute of Virology, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität
10 Berlin, Humboldt- Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany

11 5. German Centre for Infection Research (DZIF), partner site Charité, 10117 Berlin, Germany

12 6. United States Centers for Disease Control and Prevention, Atlanta, GA, United States of America

13 * These first authors contributed equally to this article

14

15 Corresponding author:

16 Iris Finci

17 World Health Organization Regional Office for Europe

18 UN City, Marmorvej 51, 2100 Copenhagen, Denmark

19 fincii@who.int

20

21 Abstract word count: 50

22 Main text word count: 1180

23 **Key words:** Azerbaijan, CoronaVac, COVID-19, healthcare workers, SARS-CoV-2, booster, vaccination,
24 vaccine effectiveness, BA.1, BA.2, Omicron

25

26 **Abstract**

27 Among Azerbaijani healthcare workers (HCWs), compared to primary vaccine series, CoronaVac
28 booster relative vaccine effectiveness was 60% (95% CI:25–79) and 79% (95% CI:44–92) against
29 symptomatic and medically attended illness, respectively, during an Omicron BA.1/BA.2 period. Our
30 results support timely CoronaVac booster uptake among Azerbaijani HCWs to reduce morbidity.

31

32

33

34

35

36

37

38

39

40

41

42

43 **Main text**

44 COVID-19 vaccination has been critical in reducing COVID-19-related morbidity and mortality (1,2).
45 Vaccinating healthcare workers (HCWs) against COVID-19 is vital for more resilient healthcare systems;
46 HCWs face high SARS-CoV-2 exposure, regularly interact with vulnerable patients, and are essential for
47 the continuous functioning of health services. In Azerbaijan, an upper-middle income country, HCWs
48 have been prioritized for COVID-19 vaccination throughout the vaccination campaign. CoronaVac
49 (CN02 strain, Sinovac, Beijing) has mainly been used. While inactivated vaccines like CoronaVac have
50 been widely used in low- and middle-income countries, including those in the WHO European Region,
51 few studies have evaluated their effectiveness, particularly during the period characterised by
52 circulation of Omicron variants BA.1, BA.2 and BA.4/5 (hereafter 'Omicron period') (3–8).

53 Understanding COVID-19 vaccine effectiveness is essential for guiding vaccine policy. Additionally,
54 having local data showing effectiveness of COVID-19 vaccines can help promote vaccine uptake. Using
55 a prospective cohort of HCWs in Azerbaijan, we previously estimated that vaccine effectiveness (VE) of
56 two-dose primary vaccine series (PVS) against symptomatic SARS-CoV-2 infection was 19% during a
57 Delta-predominant period (9). In this study, we the same cohort to estimate relative VE (rVE) of a
58 CoronaVac booster dose compared to PVS against symptomatic SARS-CoV-2 infection during an
59 Omicron-predominant period.

60

61 **The study**

62 This cohort study has been described previously (9,10). Briefly, in mid-2021, we enrolled HCWs from
63 seven hospitals in Baku and collected information on sociodemographics, occupational exposure, and
64 COVID-19 vaccination status. Participants completed weekly symptom questionnaires, those reporting

65 any respiratory symptom were tested for SARS-CoV-2 by RT-PCR. We administered questionnaires to
66 PCR-positive participants 30 days post-symptom onset to obtain information about their illness course.
67 Data on vaccination and SARS-CoV-2 PCR testing results were validated using national databases.

68 We restricted the analysis to participants eligible for booster doses according to the Azerbaijan
69 government: those who had received PVS at least five months (150 days) prior. During January 1 –
70 August 31, 2022, we estimated the rVE of a first booster compared to a PVS series against two
71 outcomes: i) symptomatic PCR-confirmed SARS-CoV-2 infection (COVID-19) and ii) medically attended
72 COVID-19, defined as an outpatient visit because of COVID-19. Participants were considered fully
73 vaccinated 14 days after receiving their PVS and 7 days after receiving their booster dose. We assessed
74 the effect of time since vaccination on rVE against symptomatic infection over the time intervals: 7–89,
75 90–150 and ≥ 150 days following booster dose.

76 We evaluated rVE during the overall study period and separately for the period in which SARS-CoV-
77 2 Omicron BA.1 and BA.2 variants were predominantly circulating (January 1–March 31, 2022), which
78 we defined using whole genome sequencing data from study samples and publicly available data from
79 GISAID (Figure S2) (9,11).

80 Relative VE was estimated as $(1 - \text{adjusted hazard ratio}) * 100$. Hazard ratios comparing vaccinated
81 and unvaccinated participants were estimated using Cox proportional hazards models with vaccination
82 as a time-varying exposure and a calendar timescale. Hospital location (urban or sub-urban) and
83 previous SARS-CoV-2 infection were included in the model as fixed effects. Additional details about
84 study methods are included in the supplemental material. The study was approved by the Azerbaijan
85 and WHO Research Ethics Review Committees. All study participants provided written informed
86 consent.

87 At the study start, there were 1367 participants (Figure S1). The median age was 48 (IQR: 39–57),
88 and 1276 (93%) were female. Overall, 506 (37%) were nurses, 349 (26%) were physicians, and 512
89 (37%) were other professions. Overall, 375 (27%) had received PVS, 939 (69%) had received a booster,
90 30 (2%) received one vaccine dose, and 23 (2%) remained unvaccinated. Only participants who
91 received CoronaVac vaccine were included in the analysis (Table 1). The median time from receiving
92 the last vaccine dose until the start of follow-up was 66 days (IQR: 56–96) for booster dose and 150
93 days (IQR: 150–187) for PVS. At the study end, 1186 (87%) participants had received a CoronaVac
94 booster dose (Table S1).

95 During the study period, 74 participants (5%) had PCR-confirmed COVID-19, of whom 53 (72%) had
96 been vaccinated with a booster dose and 17 (23%) with PVS. Most cases [66 (89%)] occurred between
97 January and March 2022, mirroring the trends in COVID-19 incidence in Azerbaijan (Figure 1). Among
98 the participants with PCR-confirmed SARS-CoV-2, 24 (32%) sought outpatient medical care. There were
99 no emergency room visits, hospitalisations, or deaths among participants.

100 For the whole analysis period (January–August 2022), the rVE was 59% (95% CI: 24–78) against
101 symptomatic infection and 78% (95% CI: 41–92) against medically attended infection. During the
102 Omicron BA.1/BA.2-predominant period (January–March 2022), rVE of a CoronaVac booster was 60%
103 (95% CI: 25–79) against symptomatic infection and 79% (95% CI: 44–92) against medically attended
104 COVID-19 (Figure 2, Table 2). Relative VE against symptomatic infection was 50% (95% CI: -3–75) 7-89
105 days post-booster, 67% (95% CI: 35–83) 90-149 days post-booster, and 48% (95% CI: -190–91) ≥150
106 days post-booster during the whole study period. (Figure 2, Table 2).

107

108 **Conclusions**

109 Among HCWs in Azerbaijan, a CoronaVac booster dose offered additional protection against
110 symptomatic infection and medically attended infection compared to CoronaVac PVS during an
111 Omicron period. This protection, which lasted at least five months, occurred in a cohort that already
112 had rates of prior infection approaching 70% in mid-2021 (9), highlighting the importance of the
113 booster dose in reducing COVID-19 morbidity, even among HCWs with high rates of previous infection.
114 The importance of the booster dose is relevant for the general population of Azerbaijan too, where
115 COVID-19 PVS uptake is 47% and booster dose uptake is 34% (12).

116 Other studies have found variable rVE and absolute VE of a CoronaVac booster dose. A Brazilian
117 study estimated a lower rVE of booster CoronaVac against symptomatic disease of 5% at 8-59 days
118 after receipt; rVE subsequently declined to zero after 60 days in that study (5). Uncontrolled bias may
119 have contributed to the low and negative estimates against symptomatic infection in that study (13).
120 The same study estimated an rVE of booster CoronaVac against hospitalization of 47% during the same
121 time period (5). In Hong Kong, in a mainly infection-naïve population, estimated absolute VE of
122 CoronaVac booster against symptomatic BA.2 infection was 42% (3). In Brazil, in a population with
123 higher seroprevalence, absolute VE of a CoronaVac booster dose was 9% (5); in another Brazilian study,
124 CoronaVac booster dose absolute VE was 38% among persons with previous infection (7). CoronaVac
125 booster absolute VE against severe disease during Omicron BA.1/BA.2 period was high in studies in
126 both Hong Kong Special Administrative Region (85%) (4) and Brazil (74%) (5).

127 The strengths of our study include its prospective cohort design and close follow-up of
128 participants. Moreover, this is one of few studies to evaluate inactivated COVID-19 vaccine in the WHO
129 European Region. Our study also had limitations. The precision of rVE estimates was limited because of
130 the low number of events. We could not measure absolute VE of a COVID-19 booster because of the

131 small number of unvaccinated participants. We were not powered to estimate VE against severe
132 outcomes like hospitalization and death. Most infections occurred during Omicron BA.1/BA.2
133 circulation, so VE estimates should be understood in that context.

134 In conclusion, our results highlight the additional preventive benefit of CoronaVac booster vaccine
135 against symptomatic and medically attended infection and provide evidence to encourage uptake of
136 future booster doses among HCWs and the general population in Azerbaijan.

137

138 Iris Finci is infectious disease epidemiologist. She is currently a consultant epidemiologist in WHO
139 Regional Office for Europe coordinating COVID-19 and influenza vaccine effectiveness studies in
140 European region. Her primary research interests include viral respiratory infections, tuberculosis and
141 strengthening of disease surveillance.

142

143 **Author contributions**

144 GH, MAK, NS, SM, and RP conceived the cohort study on which this analysis is based. MAK, LD, NS, SM,
145 CJM, RP, GH, MYRC, and EK planned and implemented the study, including the development of study
146 protocols, data quality checks, and acquisition of data. IF, NS and MAK conceived the article. IF and NS
147 drafted the manuscript and performed the literature search. MYRC performed the data analysis with
148 support from EK. SM, MYRC and EK directly accessed and verified the raw data and take responsibility
149 for the integrity and accuracy of the analyses. BM and CD performed sequencing of study samples. All
150 authors contributed to the interpretation of the results and critically revised the manuscript. All
151 authors had full access to all the data reported in the study and accept responsibility to submit the
152 paper for publication.

153

154 **Acknowledgements**

155 Javahir Suleymanova (World Health Organization, Country Office Azerbaijan), Alina Guseinova,
156 Radu Cojocaru (World Health Organization, Regional Office for Europe, Denmark), Trent M. Herdman,
157 Jason Doran (UK Field Epidemiology Training Programme, United Kingdom), Caleb Ward (US Centers
158 for Disease Control, Georgia), Kathryn Lafond (US Centers for Disease Control, USA), Jörn Beheim-
159 Schwarzbach, Victor M. Corman, and Terry C. Jones (Institute of Virology, Charité-Universitätsmedizin
160 Berlin, corporate member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin
161 Institute of Health, Berlin, Germany; and German Centre for Infection Research (DZIF), partner site
162 Charité, Berlin, Germany); Marta Valenciano and Alain Moren (Epiconcept, France).The Sorgular.az
163 platform was developed by the Public Health and Reform Center of the Azerbaijan Ministry of Health
164 with support from the United Nations Development Program and United Nations Population Fund.

165

166 **Disclaimer**

167 The findings and conclusions in this report are those of the author(s) and do not necessarily represent
168 the views of the Centers for Disease Control and Prevention. The authors affiliated with the World
169 Health Organization (WHO) are alone responsible for the views expressed in this publication and they
170 do not necessarily represent the decisions or policies of the WHO.

171

172 **Financial statement**

173 This study was funded by The Task Force for Global Health and World Health Organisation Regional
174 Office for Europe.

175

176 **Conflict of interest**

177 None of the authors have conflict of interest.

178

179 **References**

- 180 1. Meslé MM, Brown J, Mook P, Hagan J, Pastore R, Bundle N, et al. Estimated number of deaths
181 directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO
182 European Region, December 2020 to November 2021. *Euro Surveill Bull Eur sur les Mal Transm*
183 *= Eur Commun Dis Bull.* 2021 Nov;26(47).
- 184 2. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of
185 COVID-19 vaccination: a mathematical modelling study. *Lancet Infect Dis* [Internet].
186 2022;22(9):1293–302. Available from: [http://dx.doi.org/10.1016/S1473-3099\(22\)00320-6](http://dx.doi.org/10.1016/S1473-3099(22)00320-6)
- 187 3. Tsang NNY, So HC, Cowling BJ, Leung G, Ip DKM. Effectiveness of BNT162b2 and CoronaVac
188 COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron
189 BA.2 in Hong Kong: a prospective cohort study. *Lancet Infect Dis* [Internet]. 2023;23(4):421–34.
190 Available from: [http://dx.doi.org/10.1016/S1473-3099\(22\)00732-0](http://dx.doi.org/10.1016/S1473-3099(22)00732-0)
- 191 4. Wei Y, Jia KM, Zhao S, Hung CT, Mok CKP, Poon PKM, et al. Estimation of Vaccine Effectiveness
192 of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-
193 CoV-2 Omicron. *JAMA Netw Open.* 2023;6(2):1–13.
- 194 5. Ranzani OT, Hitchings MDT, de Melo RL, de França GVA, Fernandes C de FR, Lind ML, et al.
195 Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters
196 against Omicron in Brazil. *Nat Commun.* 2022;13(1):1–10.

- 197 6. Huang Z, Xu S, Liu J, Wu L, Qiu J, Wang N, et al. Effectiveness of inactivated COVID-19 vaccines
198 among older adults in Shanghai: retrospective cohort study. *Nat Commun.* 2023;14(1):2009.
- 199 7. Cerqueira-Silva T, de Araujo Oliveira V, Paixão ES, Florentino PTV, Penna GO, Pearce N, et al.
200 Vaccination plus previous infection: protection during the omicron wave in Brazil. *Lancet Infect*
201 *Dis.* 2022;22(7):945–6.
- 202 8. Johns Hopkins Bloomberg School of Public Health. International Vaccine Access Center (IVAC)
203 [Internet]. 2023 [cited 2023 Jul 4]. Available from: [https://view-](https://view-hub.org/vaccine/covid/effectiveness-studies)
204 [hub.org/vaccine/covid/effectiveness-studies](https://view-hub.org/vaccine/covid/effectiveness-studies)
- 205 9. Katz MA, Rojas Castro MY, Seyidov N, Herdman MT, Mehdiyev S, McKnight CJ, et al. The
206 effectiveness of primary series CoronaVac vaccine in preventing COVID-19 illness: A prospective
207 cohort study among healthcare workers in Azerbaijan, May–November 2021. *Influenza Other*
208 *Respi Viruses* [Internet]. 2023;17(10):e13147. Available from:
209 <https://onlinelibrary.wiley.com/doi/abs/10.1111/irv.13147>
- 210 10. World Health Organization Regional Office for Europe. Cohort study to measure COVID-19
211 vaccine effectiveness among health workers in the WHO European Region: guidance document.
212 World Health Organization. Regional Office for Europe; 2021.
- 213 11. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data – from vision to reality.
214 *Eurosurveillance* [Internet]. 2017;22(13). Available from:
215 <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2017.22.13.30494>
- 216 12. WHO Regional Office for Europe. WHO/Europe COVID-19 Vaccine Programme Monitor
217 [Internet]. Available from: [https://worldhealthorg.shinyapps.io/EURO_COVID-](https://worldhealthorg.shinyapps.io/EURO_COVID-19_vaccine_monitor/)
218 [19_vaccine_monitor/](https://worldhealthorg.shinyapps.io/EURO_COVID-19_vaccine_monitor/)

- 219 13. Bodner K, Irvine MA, Kwong JC, Mishra S. Observed negative vaccine effectiveness could be the
 220 canary in the coal mine for biases in observational COVID-19 studies [Internet]. Vol. 131,
 221 International Journal of Infectious Diseases. 2023. p. 111–4. Available from:
 222 <https://pubmed.ncbi.nlm.nih.gov/33276180/>
- 223 14. World Health Organisation. WHO COVID-19 Dashboard [Internet]. 2023. Available from:
 224 <https://covid19.who.int/>

225
226
227
228
229

230 **Table 1. Demographic and occupational characteristics of health care worker participants by vaccination**
 231 **status on the first day of the follow-up period (n=1367), Azerbaijan, 2022**

	All Participants, N=1367	Unvaccinated, N=23	Partially vaccinated (one dose), N=30	Vaccinated with primary vaccine series (two doses), N=375	Vaccinated with booster dose (third dose), N=939
Age, N=1367					
Median (IQR)	48 (39-57)	51 (37-62.5)	43 (35-58.8)	47 (38-56)	49 (40-57)
Age group, years, N=1367					
20-29, n (%)	73 (5)	3 (13)	1 (3)	29 (8)	40 (4)
30-39, n (%)	290 (21)	6 (26)	12 (40)	84 (22)	188 (20)
40-49, n (%)	371 (27)	2 (9)	4 (13)	96 (26)	269 (29)
50-59, n (%)	416 (30)	4 (17)	8 (27)	110 (29)	294 (31)
60+, n (%)	217 (16)	8 (35)	5 (17)	56 (15)	148 (16)
Sex, N=1367					
M, n (%)	91 (7)	1 (4)	4 (13)	21 (6)	65 (7)
F, n (%)	1276 (93)	22 (96)	26 (87)	354 (94)	874 (93)
Hospital, N=1367					
Hospital 7, n (%)	269 (20)	4 (17)	2 (7)	40 (11)	223 (24)
Hospital 15, n (%)	122 (9)	0 (0)	1 (3)	8 (2)	113 (12)
Hospital 18, n (%)	204 (15)	1 (4)	3 (10)	56 (15)	144 (15)
Hospital 23, n (%)	95 (7)	3 (13)	6 (20)	29 (8)	57 (6)
Hospital 24, n (%)	191 (14)	6 (26)	5 (17)	82 (22)	98 (10)

Hospital 26, n (%)	359 (26)	2 (9)	10 (33)	107 (29)	240 (26)
Hospital 29, n (%)	127 (9)	7 (30)	3 (10)	53 (14)	64 (7)
Hospital Location, N=1367					
Urban, n (%)	517 (38)	7 (30)	9 (30)	146 (39)	355 (38)
Sub-urban, n (%)	850 (62)	16 (70)	21 (70)	229 (61)	584 (62)
Occupation/Role in hospital, N=1367					
Nurse or Midwife, n (%)	506 (37)	7 (30)	11 (37)	142 (38)	346 (37)
Medical Doctor, n (%)	349 (26)	7 (30)	8 (27)	101 (27)	233 (25)
Other, n (%)	512 (37)	9 (39)	11 (37)	132 (35)	360 (38)
BMI, N=1367					
Underweight or normal, n (%)	382 (28)	8 (35)	6 (20)	110 (29)	258 (27)
Overweight, n (%)	509 (37)	9 (39)	7 (23)	129 (34)	364 (39)
Obese, n (%)	476 (35)	6 (26)	17 (57)	136 (36)	317 (34)
Smoking, N=1367					
Currently smokes, n (%)	38 (3)	1 (4)	1 (3)	6 (2)	30 (3)
Never smokes, n (%)	1315 (96)	22 (96)	27 (90)	368 (98)	898 (96)
Smoked previously, n (%)	14 (1)	0 (0)	2 (7)	1 (<1)	11 (1)
Any chronic condition, N=1367					
No, n (%)	820 (60)	14 (61)	14 (47)	212 (57)	580 (62)
Yes, n (%)	547 (40)	9 (39)	16 (53)	163 (43)	359 (38)
Number of chronic conditions, N=1367					
0, n (%)	820 (60)	14 (61)	14 (47)	212 (57)	580 (62)
1, n (%)	383 (28)	4 (17)	10 (33)	104 (28)	265 (28)
≥2, n (%)	164 (12)	5 (22)	6 (20)	59 (16)	94 (10)
Number of household members, N=1280					
1-3, n (%)	500 (39)	12 (55)	10 (34)	138 (39)	340 (39)
4-5, n (%)	654 (51)	6 (27)	15 (52)	174 (49)	459 (52)
≥6, n (%)	126 (10)	4 (18)	4 (14)	41 (12)	77 (9)
Hands on care, N=1367					
No, n (%)	798 (58)	14 (61)	18 (60)	200 (53)	566 (60)
Yes, n (%)	569 (42)	9 (39)	12 (40)	175 (47)	373 (40)
Previous COVID-19 PCR confirmed infection, N=1367					
0, n (%)	1114 (81)	19 (83)	12 (40)	233 (62)	850 (91)
1, n (%)	253 (19)	4 (17)	18 (60)	142 (38)	89 (9)
Delay between 2nd dose and start of follow-up (days), N=1314					
Median (IQR)	305 (183-313)			150 (150-187)	309 (274-316)
Delay between 3rd dose and start of follow-up (days), N=939					
Median (IQR)	66 (56-92)				66 (56-92)
COVID-19 vaccination status and vaccine brand at study period start, N=1367					
Unvaccinated	23 (2)	23 (100)			
CoronaVac - 2 doses, n (%)	375 (27)			375 (100)	
CoronaVac - 3 doses, n (%)	939 (69)				939 (100)
CoronaVac - 1 dose, n (%)	30 (2)		30 (100)		

232

233

Table 2. Relative COVID-19 vaccine effectiveness of CoronaVac booster dose compared to CoronaVac primary vaccine series against symptomatic and medically attended SARS-CoV-2 infection during a period of Omicron and relative vaccine effectiveness against symptomatic SARS-CoV-2 infection by time since receiving booster dose, Azerbaijan, January 1 – August 31, 2022

		N	Total person-time (days)	Symptomatic COVID-19 PCR-confirmed infections	Unadjusted HR	(95% CI)	Adjusted HR	(95% CI)	Relative vaccine effectiveness (%)	(95% CI)
Symptomatic infection	Full period (Jan-Aug 2022)	1306								
	2 doses, ≥150d from 2nd dose	386	19964	16						
	≥ 7d from 3rd dose	1184	232127	53	0.4	(0.7; 0.2)	0.4	(0.8; 0.2)	58.9	(24.3; 77.6)
	BA.1/BA.2 Omicron period (Jan-Mar 2022)	1253								
Symptomatic infection	2 doses, ≥150d from 2nd dose	334	9221	15						
	≥ 7d from 3rd dose	1142	82575	48	0.4	(0.7; 0.2)	0.4	(0.8; 0.2)	60.1	(24.7; 78.8)
	Full period (Jan-Aug 2022)	1306								
	2 doses, ≥150d from 2nd dose	386	19964	8						
Medically attended infection	≥ 7d from 3rd dose	1184	232127	15	0.2	(0.6; 0.1)	0.2	(0.6; 0.1)	77.7	(41.4; 91.5)
	BA.1/BA.2 Omicron period (Jan-Mar 2022)	1253								
	2 doses, ≥150d from 2nd dose	334	9221	7						
	≥ 7d from 3rd dose	1142	82575	13	0.3	(0.6; 0.1)	0.2	(0.6; 0.1)	79.1	(43.5; 92.3)
Time since vaccination										
Symptomatic infection	Full period (Jan-Aug 2022)	1306								
	2 doses, ≥150d from 2nd dose	386	19964	16	Reference		Reference		Reference	
	7-89 days since 3rd dose	929	42710	23	0.5	(1; 0.3)	0.5	(1; 0.2)	49.7	(-3.1; 75.4)
	90-149 days since 3rd dose	1104	59588	24	0.4	(0.7; 0.2)	0.3	(0.7; 0.2)	66.9	(35; 83.2)
	≥150 days since 3rd dose	1038	130127	6	0.5	(2.3; 0.1)	0.5	(2.9; 0.1)	48.2	(-190.3; 90.8)
	BA.1/BA.2 Omicron period (Jan-Mar 2022)	1253								
	2 doses, ≥150d from 2nd dose	334	9221	15	Reference		Reference		Reference	
	7-89 days since 3rd dose	890	31828	22	0.4	(0.9; 0.2)	0.4	(0.9; 0.2)	55.1	(9.6; 77.7)

90-149 days since 3rd dose	857	39158	24	0.4	(0.7; 0.2)	0.3	(0.7; 0.2)	67.1	(34.4; 83.5)
≥150 days since 3rd dose	464	11848	2	0.6	(3.2; 0.1)	0.7	(3.6; 0.1)	34.8	(-261.5; 88.2)

*All rVE estimates were adjusted by hospital site (urban or suburban) and previous PCR-confirmed SARS-CoV-2 infection; HR – hazard ratio




Figure 1. Number of symptomatic PCR-confirmed SARS-CoV-2 positive healthcare workers by vaccination status and symptom onset, and number of SARS-CoV-2 cases in Azerbaijan (14), January-August 2022




Figure 2. Relative vaccine effectiveness of a CoronaVac booster dose compared to CoronaVac primary series, Azerbaijan, 2022

Left panel – symptomatic SARS-CoV-2 infection, total rVE (red) and stratified by time since vaccination (blue); Right panel – medically attended SARS-CoV-2 infection. Star (*) indicates that the scale was cut off.